Colon Cancer Home > Stivarga and Breastfeeding
The manufacturer of Stivarga (regorafenib) recommends that women who are breastfeeding either use Stivarga or breastfeed, but not do both. Although it is unknown if this drug passes through breast milk, it might put a nursing infant at risk for problems. Because every woman's situation is different, talk to your healthcare provider about the benefits and risks of taking this drug while breastfeeding.
Stivarga® (regorafenib) is a prescription medication approved for use in the treatment of colon or rectal cancer that has spread to other areas of the body (metastatic colorectal cancer). At this time, it is not known whether Stivarga passes through breast milk. The manufacturer of the medicine recommends women either breastfeed or use Stivarga, but not do both.
In animal studies, Stivarga was shown to pass through the breast milk of rats. The medication has not been studied in women who are nursing. Therefore, it is unknown whether the drug passes through breast milk, or if it would harm a nursing child.
Although this lack of information is certainly frustrating, it is important to note that most medicines are not studied in breastfeeding women. This is because such studies would potentially expose a nursing child, who would otherwise usually not benefit from the medicine, to possible risks.
Stivarga is associated with potentially serious side effects, including liver damage and the risk for internal bleeding. Until more information is known about the potential effects of Stivarga on a nursing infant, it is probably safest to avoid breastfeeding during Stivarga treatment.
You should discuss breastfeeding and Stivarga use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.